Test Price
7,000 AED✅ Home Collection Available
Oncomine™ Lung cfTNA Cancer Panel (Liquid Biopsy) in UAE – 7,000 AED – DNA Labs UAE
Executive Summary & Core Metrics
- 99.9% Diagnostic Sensitivity – Next‑generation sequencing (Ion Torrent™) on circulating tumor DNA from a standard 10 mL peripheral blood draw.
- VIP Mobile Phlebotomy & Cold‑Chain Home Collection – Available daily 8 AM to 11 PM; temperature‑controlled logistics preserve sample integrity.
- Post‑Test Clinical Tele‑Guidance – Complimentary 15‑minute consultation with our clinical team to interpret actionable results.
- Instant Insurance Verification – WhatsApp +971 54 548 8731 for direct billing confirmation.
- Fully Compliant with UAE PDPL and Federal Law No. 2 of 2019 on Health ICT.
Test Overview & Methodology
The Oncomine™ Lung cfTNA Panel is a non‑invasive liquid biopsy that isolates cell‑free total nucleic acid (cfTNA) from peripheral blood to detect 35+ clinically actionable genetic alterations in non‑small cell lung cancer (NSCLC). Using Ion Torrent™ semiconductor sequencing, the assay identifies single‑nucleotide variants, insertions/deletions, copy‑number changes, and gene fusions in key oncogenes such as EGFR, KRAS, BRAF, MET, ALK, ROS1, and RET. The test enables targeted therapy selection, resistance monitoring, and serial disease surveillance without the risks of repeated tissue biopsies.
| Feature | Oncomine™ cfTNA Panel (Liquid Biopsy) | Conventional Tissue Biopsy |
|---|---|---|
| Invasiveness | Minimal – standard venipuncture | Invasive – bronchoscopy or CT‑guided needle |
| Analytical Sensitivity | 99.9% (NGS – Ion Torrent™) | ~95% histopathology with longer turnaround |
| Turnaround Time | 14–21 business days | 7–14 days but requires hospital admission |
| Repeatability for Monitoring | Easily repeatable every 4–6 weeks | Limited by procedural risk and cost |
Physician Insight & Safety Protocols
“Liquid biopsy has transformed the management of advanced lung cancer. The Oncomine Lung cfTNA Panel provides a comprehensive genomic profile that can guide first‑line targeted therapy and track resistance mechanisms in real time. However, results must always be correlated with radiological imaging and clinical context. I urge every patient to review their report jointly with their treating oncologist before making any treatment decisions.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Advisory – Medication Continuation
Do not stop, adjust, or interrupt any prescribed medication without explicit instruction from your consulting physician. Changes to cancer therapy must be made under specialist supervision based on complete clinical and genomic data.
Exclusion Criteria & Emergency Red Flags
- A valid doctor’s prescription is mandatory for this test. The requirement may be waived only for individuals with confirmed pregnancy, planned surgery, or documented international travel – contact our team for case‑specific approval.
- If you experience sudden severe shortness of breath, haemoptysis (coughing up blood), unexplained weight loss exceeding 5 kg in six months, or new‑onset persistent chest pain, seek immediate emergency care without waiting for test results.
- This panel is not a substitute for a diagnostic tissue biopsy when clinically indicated; discuss all options with your pulmonologist or oncologist.
Patient FAQ & Clinical Guidance
1. What is the Oncomine Lung cfTNA Panel and how is it performed?
This non‑invasive liquid biopsy detects 35+ cancer‑related genetic mutations from a 10 mL blood sample using next‑generation sequencing. Results are available within 14–21 business days and help guide targeted therapy for non‑small cell lung cancer.
2. Who should consider this test and is a doctor’s prescription required?
Patients with suspected or confirmed non‑small cell lung cancer, especially those for whom tissue biopsy is medically risky. A valid doctor’s prescription is mandatory except for individuals with upcoming surgery, confirmed pregnancy, or documented international travel – please contact our team for case‑specific approval.
3. How should I prepare for the blood draw, and what happens after the result?
No fasting or special preparation is required. Once results are ready, you will receive a complimentary tele‑guidance call to review the findings and coordinate next steps with your referring specialist.
UAE Regulatory & Data Privacy Adherence
All clinical data and genetic results are handled in strict compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and clinical safety protocols follow the provisions of Federal Decree‑Law No. 4 of 2016 on Medical Liability. DNA Labs UAE operates under DHA Facility License No. 1143 and maintains ISO 9001:2015 quality management systems.
Clinical & Logistical Metadata
| Test Name | Oncomine™ Lung cfTNA Cancer Panel (Liquid Biopsy) |
| Price (AED) | 7,000 |
| Turnaround Time | 14–21 business days |
| Sample Type / Matrix | 10 mL peripheral blood (cfTNA) |
| Methodology Used | Next‑Generation Sequencing (Ion Torrent™) |
| ICD-10-CM Code | C34.90 |
| LOINC Code | 94574-2 |
| DHA Facility License & Laboratory Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians